MSFT 415.85 -0.4643% AAPL 228.66 0.1665% NVDA 145.315 -1.153% GOOGL 175.65 -1.3867% GOOG 177.07 -1.3977% AMZN 202.88 -0.8455% META 564.135 0.5427% AVGO 162.61 -1.6571% TSLA 342.2799 -1.0752% TSM 186.825 -1.5% LLY 754.385 3.3786% V 307.39 -1.4302% JPM 240.935 -0.8865% UNH 601.41 4.2305% NVO 105.52 2.8159% WMT 87.12 0.6005% LVMUY 121.8 -0.5471% XOM 119.97 1.1296% LVMHF 607.0 -0.9465% MA 512.64 -1.3129%
Last update at 2024-11-20T20:34:00Z
Goldman Sachs: Merck & Co., Inc. (NYSE:MRK) Is A Stock With High Consensus ROE
Sat 19 Oct 24, 03:57 PMMerck & Co. (MRK): Strong Growth Driven by Keytruda and New Vaccine Approvals
Fri 18 Oct 24, 07:25 PMInvestors in Merck (NYSE:MRK) have seen respectable returns of 48% over the past three years
Fri 18 Oct 24, 12:00 PMMerck & Co., Inc. (MRK): Among the Blue Chip Stocks With Low PE Ratios
Fri 18 Oct 24, 07:20 AMIs Merck & Co., Inc. (MRK) the Most Promising Long-Term Stocks According to Hedge Funds?
Thu 17 Oct 24, 10:34 PMMerck (MRK): Promising Long-Term Stock with Strategic Acquisitions
Thu 17 Oct 24, 05:41 PMBernstein starts healthcare sector, rates three stocks as Buy
Thu 17 Oct 24, 10:05 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 16444.00M | 13879.00M | 8791.00M | 11464.00M | 8701.00M |
| Minority interest | -7.00000M | 691.00M | 15.00M | -66.00000M | -27.00000M |
| Net income | 14519.00M | 13049.00M | 7067.00M | 9843.00M | 6220.00M |
| Selling general administrative | 9772.00M | 9293.00M | 10468.00M | 10615.00M | 10102.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 41872.00M | 35078.00M | 32509.00M | 32728.00M | 28785.00M |
| Reconciled depreciation | 3909.00M | 3214.00M | 3625.00M | 3652.00M | 4519.00M |
| Ebit | 14710.00M | 10646.00M | 5436.00M | 9227.00M | 5731.00M |
| Ebitda | 18619.00M | 13860.00M | 9061.00M | 12879.00M | 10250.00M |
| Depreciation and amortization | 3909.00M | 3214.00M | 3625.00M | 3652.00M | 4519.00M |
| Non operating income net other | -1501.00000M | 1341.00M | 886.00M | -139.00000M | 402.00M |
| Operating income | 14710.00M | 10646.00M | 5436.00M | 9227.00M | 8931.00M |
| Other operating expenses | 41001.00M | 35505.00M | 39511.00M | 34599.00M | 33363.00M |
| Interest expense | 962.00M | 806.00M | 831.00M | 893.00M | 772.00M |
| Tax provision | 1918.00M | 1521.00M | 1709.00M | 1687.00M | 2508.00M |
| Interest income | 1348.00M | 1884.00M | 59.00M | 274.00M | 343.00M |
| Net interest income | -805.00000M | -770.00000M | -772.00000M | -619.00000M | -429.00000M |
| Extraordinary items | 0.00000M | 704.00M | 2548.00M | -117.00000M | -289.00000M |
| Non recurring | 337.00M | 661.00M | 578.00M | 638.00M | 632.00M |
| Other items | - | - | - | - | - |
| Income tax expense | 1918.00M | 1521.00M | 1709.00M | 1687.00M | 2508.00M |
| Total revenue | 59283.00M | 48704.00M | 47994.00M | 46840.00M | 42294.00M |
| Total operating expenses | 23590.00M | 21879.00M | 24026.00M | 20487.00M | 19854.00M |
| Cost of revenue | 17411.00M | 13626.00M | 15485.00M | 14112.00M | 13509.00M |
| Total other income expense net | 1734.00M | 3233.00M | 3355.00M | 2237.00M | 199.00M |
| Discontinued operations | - | 704.00M | 704.00M | 704.00M | 704.00M |
| Net income from continuing ops | 14526.00M | 12358.00M | 7082.00M | 9777.00M | 6193.00M |
| Net income applicable to common shares | 14519.00M | 13049.00M | 7067.00M | 9843.00M | 6220.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 109160.00M | 105694.00M | 91588.00M | 84397.00M | 82637.00M |
| Intangible assets | 20269.00M | 22933.00M | 14604.00M | 14196.00M | 11431.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 7169.00M | 6987.00M | 5541.00M | 4277.00M | 4500.00M |
| Total liab | 63102.00M | 67437.00M | 66184.00M | 58396.00M | 55755.00M |
| Total stockholder equity | 45991.00M | 38184.00M | 25317.00M | 25907.00M | 26701.00M |
| Deferred long term liab | 1795.00M | 3441.00M | 1015.00M | 1470.00M | 1702.00M |
| Other current liab | 18029.00M | 16851.00M | 16302.00M | 14872.00M | 13580.00M |
| Common stock | 1788.00M | 1788.00M | 1788.00M | 1788.00M | 1788.00M |
| Capital stock | 1788.00M | 1788.00M | 1788.00M | 1788.00M | 1788.00M |
| Retained earnings | 61081.00M | 53696.00M | 47362.00M | 46602.00M | 42579.00M |
| Other liab | 9105.00M | 11650.00M | 12135.00M | 12672.00M | 13662.00M |
| Good will | 21204.00M | 21264.00M | 20238.00M | 19425.00M | 18253.00M |
| Other assets | 7350.00M | 9400.00M | 7846.00M | 5263.00M | 5313.00M |
| Cash | 12694.00M | 8096.00M | 8062.00M | 9676.00M | 7965.00M |
| Cash and equivalents | 12694.00M | 8096.00M | 8062.00M | 9676.00M | 7965.00M |
| Total current liabilities | 24239.00M | 23872.00M | 27327.00M | 22220.00M | 22206.00M |
| Current deferred revenue | - | - | 1015.00M | - | - |
| Net debt | 17997.00M | 25006.00M | 23729.00M | 16670.00M | 17149.00M |
| Short term debt | 1946.00M | 2412.00M | 6431.00M | 3610.00M | 5308.00M |
| Short long term debt | 1946.00M | 2412.00M | 6431.00M | 3610.00M | 5308.00M |
| Short long term debt total | 30691.00M | 33102.00M | 31791.00M | 26346.00M | 25114.00M |
| Other stockholder equity | -12110.00000M | -12871.00000M | -17199.00000M | -16290.00000M | -12121.00000M |
| Property plant equipment | 21422.00M | 19279.00M | 17986.00M | 15053.00M | 13291.00M |
| Total current assets | 35722.00M | 30266.00M | 27764.00M | 27483.00M | 25875.00M |
| Long term investments | 1015.00M | 370.00M | 785.00M | 1469.00M | 6233.00M |
| Net tangible assets | 4518.00M | 3548.00M | -9525.00000M | -7714.00000M | -2983.00000M |
| Short term investments | 498.00M | - | 785.00M | 774.00M | 899.00M |
| Net receivables | 9450.00M | 9230.00M | 7851.00M | 6778.00M | 7071.00M |
| Long term debt | 28745.00M | 30690.00M | 25360.00M | 22736.00M | 19806.00M |
| Inventory | 5911.00M | 5953.00M | 6310.00M | 5978.00M | 5440.00M |
| Accounts payable | 4264.00M | 4609.00M | 4594.00M | 3738.00M | 3318.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | 67.00M | 73.00M | 87.00M | 94.00M | 181.00M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -4768.00000M | -4429.00000M | -6634.00000M | -6193.00000M | -5545.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 1788.00M | 1788.00M | 1788.00M | 1788.00M | 1788.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 61081.00M | 53696.00M | 47362.00M | 46602.00M | 42579.00M |
| Treasury stock | - | -57109.00000M | -56787.00000M | -55950.00000M | -50929.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 7733.00M | 8141.00M | 9196.00M | 5301.00M | 5852.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 73438.00M | 75428.00M | 63824.00M | 56914.00M | 56762.00M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | 28745.00M | 30690.00M | 25360.00M | 22736.00M | 19806.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -483.00000M | 1025.00M | 1717.00M | 5420.00M | 7258.00M |
| Change to liabilities | -504.00000M | 626.00M | -307.00000M | -1821.00000M | 450.00M |
| Total cashflows from investing activities | -4960.00000M | -16421.00000M | -9443.00000M | -2629.00000M | 4314.00M |
| Net borrowings | -2251.00000M | 1631.00M | 5011.00M | 1248.00M | 837.00M |
| Total cash from financing activities | -9119.00000M | 2593.00M | -2832.00000M | -8861.00000M | -13160.00000M |
| Change to operating activities | -2068.00000M | -997.00000M | -4017.00000M | 107.00M | -1281.00000M |
| Net income | 14526.00M | 12358.00M | 7082.00M | 9777.00M | 6193.00M |
| Change in cash | 4606.00M | 14.00M | -1769.00000M | 1967.00M | 1871.00M |
| Begin period cash flow | 8167.00M | 8153.00M | 9934.00M | 7967.00M | 6096.00M |
| End period cash flow | 12773.00M | 8167.00M | 8165.00M | 9934.00M | 7967.00M |
| Total cash from operating activities | 19095.00M | 14109.00M | 10253.00M | 13440.00M | 10922.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 3909.00M | 3214.00M | 3625.00M | 3652.00M | 4519.00M |
| Other cashflows from investing activities | -89.00000M | -13132.00000M | -6476.00000M | -4576.00000M | -329.00000M |
| Dividends paid | -7012.00000M | -6610.00000M | -6215.00000M | -5695.00000M | 5172.00M |
| Change to inventory | -161.00000M | -674.00000M | -855.00000M | -508.00000M | -911.00000M |
| Change to account receivables | -644.00000M | -2033.00000M | -1002.00000M | 294.00M | -418.00000M |
| Sale purchase of stock | 384.00M | -840.00000M | -1281.00000M | -4780.00000M | -9091.00000M |
| Other cashflows from financing activities | 144.00M | 8714.00M | -436.00000M | 1614.00M | -325.00000M |
| Change to netincome | 2023.00M | 2760.00M | 1476.00M | 2078.00M | 1113.00M |
| Capital expenditures | 4388.00M | 4448.00M | 4684.00M | 3473.00M | 2615.00M |
| Change receivables | -644.00000M | -2033.00000M | -1002.00000M | 294.00M | -418.00000M |
| Cash flows other operating | 14472.00M | 10216.00M | 234.00M | -32.00000M | -24.00000M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | 5016.00M | -202.00000M | -2022.00000M | 1950.00M | 2076.00M |
| Change in working capital | -2782.00000M | -3839.00000M | -4590.00000M | -2067.00000M | -1553.00000M |
| Stock based compensation | 541.00M | 479.00M | 475.00M | 417.00M | 348.00M |
| Other non cash items | 4469.00M | 1710.00M | 4329.00M | 2217.00M | 1924.00M |
| Free cash flow | 14707.00M | 9661.00M | 5569.00M | 9967.00M | 8307.00M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MRK Merck & Company Inc |
1.02 1.06% | 97.56 | 59.83 | 12.33 | 4.50 | 6.47 | 4.94 | 23.79 |
| LLY Eli Lilly and Company |
24.66 3.38% | 754.38 | 103.14 | 46.73 | 16.88 | 48.24 | 17.43 | 69.11 |
| JNJ Johnson & Johnson |
0.20 0.13% | 153.20 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| ABBV AbbVie Inc |
1.26 0.76% | 167.83 | 42.38 | 13.68 | 4.88 | 22.14 | 5.72 | 31.93 |
| AZN AstraZeneca PLC ADR |
-0.695 1.09% | 63.10 | 38.69 | 16.31 | 4.67 | 5.46 | 5.20 | 17.74 |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV, as well as a collaboration with Bionomics to identify novel a7 nAChR PAMs suitable for the treatment of cognitive disorder; and clinical trial collaboration and supply agreement with Ankyra Therapeutics to evaluate ANK-101 in combination with KEYTRUDA (pembrolizumab) in patients with advanced solid tumors, as well as a clinical trial collaboration and supply agreement with Phanes Therapeutics, Inc. to evaluate PT886 in combination with KEYTRUDA for the treatment of claudin 18.2 positive gastric or gastroesophageal junction adenocarcinomas, as well as a development and commercialization agreement with Daiichi Sankyo Company, Limited to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates and a collaboration with HiberCell, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert M. Davis J.D. | CEO & Chairman | 1967 |
| Ms. Caroline Litchfield | Exec. VP & CFO | 1969 |
| Mr. Richard R. DeLuca Jr. | Exec. VP & Pres of Merck Animal Health | 1963 |
| Dr. Dean Y. Li M.D., Ph.D. | Exec. VP & Pres of Merck Research Laboratories | 1962 |
| Mr. David Michael Williams | Exec. VP and Chief Information & Digital Officer | 1969 |
| Mr. Peter Dannenbaum | VP of Investor Relations | NA |
| Ms. Jennifer L. Zachary | Exec. VP & Gen. Counsel | 1978 |
| Lisa LeCointe-Cephas | Sr. VP and Chief Ethics & Compliance Officer | 1982 |
| Ms. Jennifer Mauer | VP of Global Communications | NA |
| Ms. Cristal N. Downing | Exec. VP and Chief Communications & Public Affairs Officer | 1969 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...